S 44819Alternative Names: S-44819
Latest Information Update: 14 Jun 2016
At a glance
- Originator Servier
- Mechanism of Action GABA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 14 Jun 2016 Servier plans a phase II trial for Cerebral ischaemia in United Kingdom
- 18 Jan 2016 Preclinical trials in Stroke in France (PO)